Blue Earth Therapeutics

Blue Earth Therapeutics is excited to announce an expansion of the partnership and manufacturing agreements with Seibersdorf Labor GmbH to include the manufacture of 225Ac rhPSMA‐10.1, which is the second candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. This agreement provides future supply to the UK, EU and US clinical trial sites. Further details can be found on our website: https://lnkd.in/gsTXT-rw

Blue Earth Therapeutics are pleased to announce a partnership with SHINE Technologies. Blue Earth Therapeutics will utilise SHINE’s non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for patients with prostate cancer undergoing clinical trials. Visit our website to discover more: https://lnkd.in/ehT2mZ3r #radiotherapeutics #healthcare

Blue Earth Therapeutics recently presented a poster on the impact of physical half-life on therapeutic index. See below for the key points and visit https://lnkd.in/ehT2mZ3r for more   #radiopharmaceuticals #healthcare

Facing challenges with radiopharmaceutical therapy (RPT) clinical trials? Join @Nathaniel Scott and others to discuss Navigating the Complexities of RPT Clinical Trials at the OCT 2024 meeting in London, UK on June 12th. Find the agenda here: https://lnkd.in/dH7BdC3Y Or visit our website to discover more about us: https://lnkd.in/ehT2mZ3r #radiopharmaceutical #healthcare #OCT”

Congratulations Daniel Stevens! The Faculty of Pharmaceutical Medicine Fellowship recognises achievement at a high level in the profession and confers peer recognition and is well-deserved for Dan’s contributions to the field. Dan is at the forefront of our team of experts leading development of next-generation radioligand therapy. Find out more at: https://lnkd.in/ehT2mZ3r

Listen to Ben, one of our medical physicists, explain the influence and impact he has at Blue Earth Therapeutics – and what makes his role different. #Medicalphysicist #Radiotherapeutics

Welcome Felicity Lyon-Staniewski. We’re thrilled to be adding Felicity’s expertise to our growing team. At Blue Earth Therapeutics, we are navigating complex regulatory landscapes to achieve our clinical mission.   Felicity is an accomplished regulatory leader bringing a wealth of experience and expertise to Blue Earth Therapeutics.  With a deep understanding of global regulatory requirements, Felicity has a proven track record in leading complex regulatory strategies throughout development and is poised to steer the organisation towards regulatory excellence. #healthcare #radiotherapeutics

Want to be inspired by the future of biotech? We’ll be connecting with industry leaders and experts at Bio€quity 2024. Join us there or visit our website to discover more: https://lnkd.in/ehT2mZ3r #healthcare #radiotherapeutics #bioequity

How can we judge the impact of half-life and pharmacokinetics on efficacy of RLT? BNMS 2024 is a great chance to discuss this and much more. On the 15th of May in Belfast our Medical Physicist Nathaniel Scott will be presenting the poster: "Let’s Get Physical: Why half-life matters in the development of therapeutic radionuclides" Visit our website for more: https://lnkd.in/ehT2mZ3r #healthcare #BNMS #radiotherapeutics”

"What is radioligand therapy?", is one of the many questions our resident experts get asked. It’s an innovative approach to treating certain cancer types, while minimising harm to healthy tissue.  Swipe below to learn more or visit our website at https://lnkd.in/ehT2mZ3r.  #radioligandtherapy #radiopharmaceuticals